ERBB2 and breast carcinoma: Therefore, we feel that, unlike breast cancer, tests for both IHC and FISH (for cases with IHC 2+ and 3+) are required for cervical adenocarcinoma patients in clinical trials of trastuzumab treatment, which is primarily aimed towards patients with HER2 amplification.